一直被模仿，但不曾被超越，即便被仿制，也很难被复制

参考文献：

[1] How has Humira become the king of all drugs ?

[2] Norman, Peter Humira: the impending patent battles over adalimumab biosimilars In Pharmaceutical Patent Analyst 2016, 5(3), 141–145.

[3] 张忠兵, 罗建辉. 单克隆抗体半乳糖建饰研究进展[J]. 我国医药物有机体核心技术, 2020, 15(4):6.

[4] Zhang E, Xie L, Qin P, Lu L, Xu Y, Gao W, Wang L, Xie MH, Jiang W, Liu S. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®. AAPS J. 2020 May 8;22(3):69.

[5] 程速远, 赵靖, 董莹莹,等. 关于阿达木肌肉注射有机体相同药物密度相似持续性评价要点的初步概述[J]. 我国有机体制品学周刊, 2021, v.34(05) 626-632.

[6] 陈昊.有机体相同药物的特殊持续性与监管措施概述[J].我国新药物周刊 2020年29卷11期, 1201-1204页, ISTIC PKU CSCD, 2020.

[7] Zhang H, Wu M, Sun J, Zhu X, Li C, Ding Y, Zhang X, Chai K, Li X. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study. Pharmacol Res Perspect. 2021 Apr;9(2):e00733.